Table 1.
Baseline Cytopenias and Sustained Hematologic Improvementa
| Baseline Cytopenia(s) | Sustained Hematologic Improvement in Patients With Specified Cytopenia(s) at Baseline, n/N (%) | ||||
|---|---|---|---|---|---|
| Ibrutinib (n = 195) | Ofatumumab (n = 196) | Ibrutinib | Ofatumumab | P Value | |
| Thrombocytopenia, n (%) | 74 (38) | 64 (33) | 61/74 (82) | 14/64 (22) | < .0001 |
| Median platelet count, × 109/L (range) | 65.5 (20-99) | 72 (23-100) | |||
| Neutropenia, n (%) | 41 (21) | 38 (19) | 28/41 (68) | 12/38 (32) | .0011 |
| Median neutrophil count, × 109/L (range) | 1.1 (0.4-1.5) | 1.1 (0.3-1.5) | |||
| Anemia, n (%) | 89 (46) | 86 (44) | 61/89 (69) | 32/86 (37) | < .0001 |
| Median hemoglobin, g/dL (range) | 9.8 (6.5-11) | 9.8 (6.2-11) | |||
| Any cytopenia, n (%) | 124 (64) | 123 (63) | 98/124 (79) | 53/123 (43) | < .0001 |
a
Sustained improvement ≥ 56 days without transfusions or growth factors. Blood counts assessed by central laboratory.